# ImmunityBio, Inc. (IBRX): MoatMap facts

As of 27 Oct 2026. Research data, not investment advice.

As of 27 Oct 2026, MoatMap's StockRank for ImmunityBio, Inc. (IBRX) is 30/100, ranked against 24,000+ stocks in 35 markets (Quality 32, Value 23, Momentum 62, each scored against its sector).

- StockRank: 30/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 32, Value 23, Momentum 62: each a 0-100 percentile within Healthcare.
- Position: #18,600 overall, #1,620 in Healthcare.
- Listing: United States, NMS; Healthcare / Biotechnology.
- Last close: 7.81 USD on 26 Oct 2026.
- Insider filings, last 180 days: directors sold USD 5.0M.

Source: https://moatmap.ai/stock/IBRX
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker